Literature DB >> 32206605

The role of parathyroidectomy in treating hypertension and other cardiac manifestations of primary hyperparathyroidism.

J Alex Nelson1, Mahmoud Alsayed2,3, Mira Milas3,4.   

Abstract

Among many recognized sequelae of primary hyperparathyroidism (PHPT), cardiovascular disease remains incompletely understood as a consequence of disordered calcium and parathyroid hormone (PTH) metabolism. While population studies have identified trends that associate PHPT with hypertension, metabolic syndrome, and vascular system calcifications, the fundamental pathophysiology, natural history, and opportunity to reverse or cure the cardiovascular effects with parathyroidectomy are not well established. This chapter reviews the current knowledge of this field of interest within PHPT and summarizes key findings from dedicated investigations that have addressed the impact of parathyroid surgery on the cardiovascular system. 2020 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Primary hyperparathyroidism (PHPT); cardiovascular; hypertension; non-dipping pattern; normocalcemic; parathyroidectomy

Year:  2020        PMID： 32206605      PMCID： PMC7082270          DOI： 10.21037/gs.2019.12.12

Source DB:  PubMed          Journal:  Gland Surg        ISSN： 2227-684X


  17 in total

1.  The long-term benefit of parathyroidectomy in primary hyperparathyroidism: a 10-year prospective surgical outcome study.

Authors:  Janice L Pasieka; Louise Parsons; Jean Jones
Journal:  Surgery       Date:  2009-12       Impact factor: 3.982

2.  The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism.

Authors:  Scott M Wilhelm; Tracy S Wang; Daniel T Ruan; James A Lee; Sylvia L Asa; Quan-Yang Duh; Gerard M Doherty; Miguel F Herrera; Janice L Pasieka; Nancy D Perrier; Shonni J Silverberg; Carmen C Solórzano; Cord Sturgeon; Mitchell E Tublin; Robert Udelsman; Sally E Carty
Journal:  JAMA Surg       Date:  2016-10-01       Impact factor: 14.766

3.  Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up.

Authors:  T Stefenelli; C Abela; H Frank; J Koller-Strametz; S Globits; J Bergler-Klein; B Niederle
Journal:  J Clin Endocrinol Metab       Date:  1997-01       Impact factor: 5.958

Review 4.  Who Benefits from Treatment of Primary Hyperparathyroidism?

Authors:  Catherine Y Zhu; Dalena T Nguyen; Michael W Yeh
Journal:  Surg Clin North Am       Date:  2019-05-11       Impact factor: 2.741

5.  Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism.

Authors:  Jens Bollerslev; Thord Rosen; Charlotte L Mollerup; Jörgen Nordenström; Marek Baranowski; Celina Franco; Ylva Pernow; Gunhild A Isaksen; Kristin Godang; Thor Ueland; Svante Jansson
Journal:  J Clin Endocrinol Metab       Date:  2009-04-07       Impact factor: 5.958

6.  Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy.

Authors:  Erik G Almqvist; Anne-Greth Bondeson; Lennart Bondeson; Anders Nissborg; Peter Smedgård; Sven-Eric Svensson
Journal:  Surgery       Date:  2002-12       Impact factor: 3.982

7.  Carotid vascular abnormalities in primary hyperparathyroidism.

Authors:  M D Walker; J Fleischer; T Rundek; D J McMahon; S Homma; R Sacco; S J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2009-09-15       Impact factor: 5.958

8.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop.

Authors:  John P Bilezikian; Maria Luisa Brandi; Richard Eastell; Shonni J Silverberg; Robert Udelsman; Claudio Marcocci; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

9.  Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism.

Authors:  Peter Vestergaard; Leif Mosekilde
Journal:  BMJ       Date:  2003-09-06

10.  The effect of surgery on fat mass, lipid and glucose metabolism in mild primary hyperparathyroidism

Authors:  Kristin Godang; Karolina Lundstam; Charlotte Mollerup; Fougner Fougner; Ylva Pernow; Jörgen Nordenström; Thord Rosén; Svante Jansson; Mikael Hellström; Jens Bollerslev; Ansgar Heck
Journal:  Endocr Connect       Date:  2018-08-01       Impact factor: 3.335
View more
  1 in total

1.  Effect of Yiqi Huayu Pinggan Zishen Formula Combined with Valsartan in the Treatment of Hypertension and Its Effect on MMP-9, Ang II, and MCP-1.

Authors:  Jing Yan; Defeng Li; Qin Liu; Yuanlan Xie
Journal:  Comput Math Methods Med       Date:  2022-05-06       Impact factor: 2.809
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.